Lepu Biopharma - Bamboo Works - China stock insights for global investors

FAST NEWS: Lepu Biopharma to raise $32 million in share sale

Fri, 17 May 2024 05:34:10 +0000

The Latest: Innovative drug maker Lepu Biopharma Co. Ltd. (2157.HK) announced on Friday it will place up to 51.17 million shares, or about 2.99% of its overall issued share capital, for a sale price of HK$4.58 per share. Looking Up: The company expects to receive approximately 230 million yuan ($32 million) in net proceeds from the.....

The post FAST NEWS: Lepu Biopharma to raise $32 million in share sale appeared first on Bamboo Works.

Lepu Biopharma gets taste of spring with first revenues

Thu, 23 Mar 2023 03:38:53 +0000

The ADC-focused drug company logged its first-ever sales late last year, kicking of the next phase of its development Key Takeaways: 　 By Molly Wen After years of cash burning to support its drug development and Hong Kong listing, Lepu Biopharma Co. Ltd. (2157.HK) has entered a new phase as it graduates from the ranks.....

The post Lepu Biopharma gets taste of spring with first revenues appeared first on Bamboo Works.

Laekna IPO hopes to hitch a ride on Novartis ties

Tue, 21 Mar 2023 04:25:30 +0000

The producer of drugs licensed from third parties is banking on ties to the Swiss drug maker, as one of its key products nears the regulatory finish line Key Takeaways: 　 By Ellie Si Innovative cancer drug maker Laekna Inc. was hoping to ride a wave of strong investor sentiment toward innovative drug makers when.....

The post Laekna IPO hopes to hitch a ride on Novartis ties appeared first on Bamboo Works.

Lepu Biopharma Marches Towards First Sales as Costs Mount

Thu, 06 Oct 2022 05:04:58 +0000

Company’s Puyouheng cancer immunotherapy drug was approved for two indications in China, becoming its first commercialized product Key Takeaways: Lepu Biopharma will incur more operational costs as it builds up its production capacity and sales and marketing teams to commercialize its first approved product The company’s stock surged after it said it would list on.....

The post Lepu Biopharma Marches Towards First Sales as Costs Mount appeared first on Bamboo Works.

Lepu ScienTech Revives IPO After Policy Move Brightens Its Prospects

Wed, 21 Sep 2022 04:13:01 +0000

China’s leading supplier of congenital heart disease devices made its third filing earlier this month for a Hong Kong IPO Key Takeaways: After taking its Lepu Biopharma unit public in February, Lepu Medical is pressing ahead with a third attempt at listing is Lepu ScienTech unit in Hong Kong China’s healthcare regulator has said it.....

The post Lepu ScienTech Revives IPO After Policy Move Brightens Its Prospects appeared first on Bamboo Works.

3D Medicines Bleeds Red Ink As It Struggles to Swim in ‘Red Ocean’

Fri, 29 Jul 2022 05:44:19 +0000

The loss-making innovative oncology drug company with just one approved product on the market is making a third tilt for a listing on the Hong Kong Stock Exchange Key Takeaways: 3D Medicines competes for a share in an already hotly contested and very small market, potentially dimming its appeal to investors The company lost 1.46.....

The post 3D Medicines Bleeds Red Ink As It Struggles to Swim in ‘Red Ocean’ appeared first on Bamboo Works.

With Zero Revenue, Laekna Plays Chicken-And-Egg Game With Investors

Fri, 24 Jun 2022 08:09:51 +0000

The biotechnology company, which is facing ballooning losses without any revenue like many of its peers, has filed for an IPO in Hong Kong Key Takeaways: Laekna is seeking a Hong Kong IPO to raise funds to accelerate the commercialization of two core products licensed from Novartis The company currently is not generating any sales,.....

The post With Zero Revenue, Laekna Plays Chicken-And-Egg Game With Investors appeared first on Bamboo Works.